Author:
Borasio G. D.,Robberecht W.,Leigh P. N.,Emile J.,Guiloff R. J.,Jerusalem F.,Silani V.,Vos P. E.,Wokke J.H.J.,Dobbins T.,
Abstract
To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months. At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups. RhIGF-I appeared to be safe and well-tolerated.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Cited by
309 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献